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Objectives The purpose of this study was to test whether elevated nonfasting glucose levels associate with and cause isch-
emic heart disease (IHD) and myocardial infarction (MI).
Background Elevated fasting plasma glucose levels associate with increased risk of IHD, but whether this is also true for non-
fasting levels and whether this is a causal relationship is unknown.
Methods Using a Mendelian randomization approach, we studied 80,522 persons from Copenhagen, Denmark. Of those,
IHD developed in 14,155, and MI developed in 6,257. Subjects were genotyped for variants in GCK (rs4607517),
G6PC2 (rs560887), ADCY5 (rs11708067), DGKB (rs2191349), and ADRA2A (rs10885122) associated with ele-
vated fasting glucose levels in genome-wide association studies.
Results Risk of IHD and MI increased stepwise with increasing nonfasting glucose levels. The hazard ratio for IHD in sub-
jects with nonfasting glucose levels 11 mmol/l (198 mg/dl) versus 5 mmol/l (90 mg/dl) was 6.9 (95%
confidence interval [CI]: 4.2 to 11.2) adjusted for age and sex, and 2.3 (95% CI: 1.3 to 4.2) adjusted multifactori-
ally; corresponding values for MI were 9.2 (95% CI: 4.6 to 18.2) and 4.8 (95% CI: 2.1 to 11.2). Increasing num-
ber of glucose-increasing alleles was associated with increasing nonfasting glucose levels and with increased
risk of IHD and MI. The estimated causal odds ratio for IHD and MI by instrumental variable analysis for a
1-mmol/l (18-mg/dl) increase in nonfasting glucose levels due to genotypes combined were 1.25 (95% CI: 1.03
to 1.52) and 1.69 (95% CI: 1.28 to 2.23), and the corresponding observed hazard ratio for IHD and MI by Cox
regression was 1.18 (95% CI: 1.15 to 1.22) and 1.09 (95% CI: 1.07 to 1.11), respectively.
Conclusions Like common nonfasting glucose elevation, plasma glucose-increasing polymorphisms associate with increased
risk of IHD and MI. These data are compatible with a causal association. (J Am Coll Cardiol 2012;59:2356–65)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.02.043Elevated fasting plasma glucose levels are associated with
increased risk of ischemic heart disease (IHD) and myocar-
dial infarction (MI) in subjects with and without diabetes
mellitus (1,2), but it is unclear whether this is also true for
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reduce the risk of IHD and MI (3), it is unclear whether this
risk reduction is due to reduced glucose levels per se or to an
improvement of concomitant obesity, dyslipidemia, and
hypertension.
To study a potential causal relationship a Mendelian
randomization approach can be used to circumvent con-
founding and reverse causation (4). This approach uses the
fact that genetic glucose-increasing variants are randomly
assorted during gamete formation, like patients are random-
ized to placebo or active treatment in intervention trials;
and, if genotypes associated with higher plasma glucose
levels also are associated with increased risk of IHD and MI
compared to genotypes associated with lower levels, it
follows that this likely is a causal association. To use this
approach, we genotyped variants in GCK (rs4607517) (5),
G6PC2 (rs560887) (5–7), ADCY5 (rs11708067) (8), DGKB
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were selected as the variants associated with the largest
effects on fasting glucose levels in genome-wide association
studies specifically aiming to identify variants associated
with plasma glucose levels, and not previously associated
with IHD and MI (9). Furthermore, the genetic variants
have no major effects on other risk factors and, therefore,
can be used to study the impact of longstanding differences
in plasma glucose levels without known pleiotropic effects.
We tested the hypothesis that there is a potential causal
association between elevated nonfasting glucose levels and
increased risk of IHD and MI. As most subjects are in the
nonfasting state the majority of a 24-h cycle, and thus
exposed to higher glucose levels than observed through
fasting measurements, it may be more important to study
nonfasting than fasting glucose levels. First, we tested
whether elevated nonfasting glucose levels are associated
with increased risk of IHD; second, whether the selected
genotypes (5,8,10,11) are associated with elevated nonfast-
ing glucose levels; and finally, whether genotypes are asso-
ciated with increased risk of IHD and MI both as single site
genotypes and combined in instrumental variable analyses.
Methods
Subjects. Studies were approved by institutional review
boards and Danish ethical committees, and conducted
according to the Declaration of Helsinki. Participants were
all white persons and of Danish descent, and gave informed
consent. None appeared in 1 study.
The CCHS. The CCHS (Copenhagen City Heart Study)
is a prospective study of the general population initiated in
1976 to 1978 with follow-up examinations in 1981 to 1983,
1991 to 1994, and 2001 to 2003, and endpoints ascertained
from 1976 through May 2011 (12). Participants were
selected to reflect the adult Danish population ages 20 to
80 years. Data were obtained from a questionnaire, a
physical examination, and from blood samples at each
examination. Baseline nonfasting plasma glucose levels were
available on 16,568 participants attending the 1976 to 1978,
1981 to 1983, 1991 to 1994, and/or 2001 to 2003 examina-
tions. Baseline was defined as the first examination a subject
participated in. Blood samples for deoxyribonucleic acid
(DNA) extraction were available on 10,603 participants
attending the 1991 to 1994 and 2001 to 2003 examinations.
The CGPS. The CGPS (Copenhagen General Population
Study) is a cross-sectional/prospective study of the general
population initiated in 2003 with ongoing enrollment (13–
15) and endpoints ascertained from 1976 through May
2011. Participants were selected and examined exactly as in
the CCHS. At the time of genotyping, 48,614 subjects had
been included.
The CIHDS. The CIHDS (Copenhagen Ischemic Heart
Disease Study) comprises 5,109 patients from the greater
Copenhagen area referred for coronary angiography in 1991 to
2010 and 10,231 controls without IHD ascertained as for the hCGPS (13–15). In addition to a
diagnosis of IHD, these patients
also had stenosis/atherosclerosis
on coronary angiography and/or a
positive exercise electrocardiogra-
phy test, and/or MI.
Ischemic heart disease and
myocardial infarction. In all
studies, information on diagnosis
of IHD and MI according to
WHO International Classifica-
tion of Diseases (ICD) (ICD8: 410–414 and 410; and
ICD10: I20–I25 and I21) was collected and verified from
1976 through May 2011 by reviewing all hospital admis-
sions and diagnoses entered in the national Danish Patient
Registry and all causes of death in the national Danish
Causes of Death Registry. Ischemic heart disease was
angina pectoris and MI, the latter determined on the basis
of characteristic chest pain, electrocardiographic changes,
and/or elevated cardiac enzymes following the changes in
diagnostic criteria over time (16). Follow-up was 100%
complete, that is, no subject was lost to follow-up in any
study.
Genotypes. Genotyping for GCK (rs4607517), G6PC2
(rs560887), ADCY5 (rs11708067), DGKB (rs2191349), and
DRA2A (rs10885122) was by TaqMan, ABI Prism
900HT Sequence Detection System (Applied Biosystems,
oster City, California). Each run included a known non-
arrier, a heterozygous, and a homozygous control verified
y sequencing. After 2 reruns, call rates for genotypes where
99.9% for all assays. We also genotyped the MTNR1B
(rs10830963) variant, but it did not associate with nonfast-
ing glucose levels (observed per allele effect, nonfasting:
0.025 [SEM 0.01]) as reported for fasting glucose levels in
genome-wide association studies (per allele effect in litera-
ture: 0.072 [SEM 0.005]) (5,8), and were therefore ex-
cluded from further analysis.
Biochemical analyses. Colorimetric assays were used to mea-
sure nonfasting plasma glucose, total cholesterol, and high-density
lipoprotein (HDL) cholesterol (Konelab, Boehringer Mannheim,
Germany). Blood samples were taken at random irrespective of
content of or of time since the last meal.
Other covariates. Body mass index (BMI) was weight (kg)
divided by height squared (m2); metabolic syndrome was
efined as fulfilling 3 of the following 5 criteria: waist
ircumference 102 cm for men and 88 cm for women,
riglycerides1.7 mmol/l (150 mg/dl) or drug treatment for
levated triglycerides, HDL 1.0 mmol/l (40 mg/dl) in
en and 1.3 mmol/l (50 mg/dl) in women or drug
reatment for low HDL, systolic blood pressure 130 mm
g and/or diastolic blood pressure 85 mm Hg or antihy-
ertensive drug treatment, fasting glucose 5.56 mmol/l
100 mg/dl), or antidiabetic medication (17); diabetes mel-
itus was self-reported diabetes, use of antidiabetic medica-
ion, a nonfasting plasma glucose 11.0 mmol/l, and/or
Abbreviations
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systolic blood pressure 140 mm Hg (135 mm Hg for
diabetic subjects), diastolic blood pressure 90 mm Hg
(85 mm Hg for diabetics), and/or use of antihyperten-
sive medication prescribed specifically for hypertension;
current smoking, menopause status, and statin use were
also self-reported.
Statistical analyses. Data were analyzed by 2 authors
(M.B. and B.G.N.) using Stata/IC version 11.1 (StataCorp,
College Station, Texas). Two-sided p  0.05 was signifi-
cant. For trend tests using Cuzick nonparametric test and
extension of a Wilcoxon rank sum test, groups of subjects
classified by nonfasting glucose levels, genotypes, or number
of alleles were ranked according to increasing nonfasting
glucose levels and coded as 0, 1, 2, 3, and so forth.
First, to test whether nonfasting glucose associate with
increased risk of IHD and MI, Kaplan-Meier curves were
used to estimate cumulative incidence, and Cox regression
models with age as time scale and left truncation (delayed
entry) were used to estimate hazard ratios for IHD and MI
in the prospective CCHS. Analyses were conducted using
results from each participant’s first glucose measurement in
the 1976 to 1978, 1981 to 1983, 1991 to 1994, or 2001 to
2003 examinations (i.e., baseline), and data from the serial
examinations of other risk factors were used as time-
dependent covariates for multifactorial adjustment. Risk of
IHD and MI was estimated as a function of nonfasting
glucose levels in groups of 1-mmol/l (18-mg/dl) increases
versus5.0 mmol/l (90 mg/dl) and as a continuous variable,
and was corrected for regression dilution bias using a factor of
0.45 (Online Figs. 1 and 2) (18). Analyses were adjusted for:
1) age and sex; 2) multifactorially for age, sex, current smoking,
menopause, and statin use; 3) multifactorially including BMI;
4) multifactorially including total cholesterol and HDL cho-
Characteristics of ParticipantsTable 1 Characteristics of Participants
Characteristics CCHS
n 16,568
Ischemic heart disease* 4,184
Myocardial infarction* 2,327
Age, yrs 51 (40–59)
Women 53%
Body mass index, kg/m2 24.3 (22.2–26.8)
Total cholesterol, mmol/l 6.0 (5.2–6.8)
HDL cholesterol, mmol/l 1.4 (1.1–1.7)
Diabetes mellitus 2.1%
Hypertension 47%
Current smoking 53%
Menopause, women only 49%
Statin use 1.5%
Values are n, mean (range), or %. *Number of disease events at end
(Copenhagen City Heart Study), values are from the first participation
to 2003; in the CGPS (Copenhagen General Population Study), from
Disease Study), from enrollment 1994 to 2010. To convert glucose in
multiply by 39.
HDL  high-density lipoprotein.lesterol; 5) multifactorially including hypertension; and 6)
multifactorially including all of the above.
Second, to test whether genotype associate with elevated
nonfasting glucose levels, per allele effects of genotypes were
calculated in the CCHS and CGPS combined to obtain
maximal power; we used a method by Falconer, taking allele
frequency and mean nonfasting glucose levels for each
genotype into account (19).
Third, to test whether genetically elevated nonfasting
glucose levels associate with increased risk of IHD, we
tested for association between genotype and IHD and MI
risk using logistic regression in the CCHS, CGPS, and
CIHDS combined to obtain maximal power. Analyses were
adjusted for age and sex only, as genotypes were randomly
distributed across the covariates.
Finally, instrumental variable analysis by 2-stage least-
squares regression was used to assess a potential causal
relationship between elevated nonfasting glucose levels and
increased IHD and MI risk using genetic variants as
instruments for elevated nonfasting glucose levels in an
additive model; we used the CCHS, CGPS, and CIHDS
combined to obtain maximal power. Strength of the geno-
types as instruments (association of genotype with plasma
glucose) was evaluated by F-statistics from the first-stage
regression, where F 10 indicates sufficient strength to
ensure the validity of the instrumental variable analysis,
while R2 in percent is a measure of percent contribution of
enotype to the variation in plasma glucose (4). Causal odds
atios were estimated using the multiplicative generalized
ethod of moments estimator implemented in the user-
ritten Stata command “ivpois.” Altman’s method (20) was
sed to compare the causal odds ratio from the instru-
ental variable analysis with the observational multifac-
orially adjusted hazard ratio from Cox regression. Use of
1 genotype as instrumental variable reduces risk of bias
CGPS CIHDS
48,614 15,340
4,862 5,109
2,038 1,892
58 (47–67) 57 (48–66)
56% 46%
25.6 (23.2–28.5) 25.6 (23.2–28.5)
5.6 (4.9–6.3) 5.5 (4.7–6.3)
1.6 (1.3–2.0) 1.5 (1.2–1.9)
3.7% 13.2%
71% 55%
20% 26%
66% —
11% —
w-up. Other data are from enrollment into the studies: In the CCHS
tudy in either 1976 to 1978, 1981 to 1983, 1991 to 1994, or 2001
ent 2003 to 2010; and in the CIHDS (Copenhagen Ischemic Heart
l to mg/dl, multiply by 18; to convert cholesterol in mmol/l to mg/dl,of follo
in the s
enrollm
mmol/
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the causal risk estimate (21). This can be evaluated using
effect estimates (strength of the association between
genotype and glucose level) from previous independent
studies. To do this, we repeated the instrumental variable
analyses using effect estimates from published genome-
wide association studies (effect sizes shown in Fig. 2)
(5,6,8).
Results
Characteristics of the 80,522 participants in the 3 study
populations are shown in Table 1; IHD developed in 14,155
subjects and MI in 6,247. Age, BMI, total cholesterol levels,
frequency of male sex, metabolic syndrome, diabetes melli-
tus, use of insulin or oral antidiabetic medication, hyperten-
sion, smoking, menopause (women only), and statin use
were higher at higher nonfasting plasma glucose levels,
whereas HDL cholesterol levels were lower (Online
Table 1). Variation in nonfasting plasma glucose levels as a
function of time since the last meal in hours is shown in
Online Figure 1. Median values ranged from 5.66 mmol/l at
0 to 1 h after a meal to 5.08 mmol/l8 h after a meal (range
0.58 mmol/). Regression dilution on plasma glucose levels
from the 1976 to 1978 to the 1981 to 1983 examination is
shown in Online Figure 2, and was used to correct associ-
ation between nonfasting glucose and risk of IHD and MI
for regression dilution bias.
Nonfasting glucose and IHD and MI observational
estimates. Risk of IHD and MI increased stepwise with
ncreasing nonfasting glucose levels (Figs. 1 and 2). Subjects
with a level11 mmol/l had their event on average 20 years
before subjects with levels 5 mmol/l (Fig. 1). Age- and
sex-adjusted hazard ratio for IHD was 6.9 (95% confidence
interval [CI]: 4.2 to 11.2) in subjects with nonfasting plasma
glucose levels11 mmol/l (198 mg/dl) versus5 mmol/l
(90 mg/dl). Corresponding estimates were 6.2 (95% CI:
3.8 to 10.2) when adjusting multifactorially; 4.7 (95% CI:
2.8 to 7.7) multifactorially including BMI; 3.8 (95% CI: 2.2
to 6.5) multifactorially including total and HDL choles-
terol; 5.8 (95% CI: 3.6 to 9.5) multifactorially including
hypertension; and 2.3 (95% CI: 1.3 to 4.2) multifactorially
including all the above. Corresponding values for MI were
9.2 (95% CI: 4.6 to 18.2), 8.3 (95% CI: 4.2 to 16.6), 6.8
(95% CI: 3.4 to 13.7), 6.0 (95% CI: 2.8 to 13.0), 7.5 (95%
CI: 3.8 to 15.0), and 4.8 (95% CI: 2.1 to 11.2).
Genotype and nonfasting glucose. Homozygotes versus
noncarriers associated with the following increases in
nonfasting plasma glucose levels: GCK (rs4607517) 2.7%
(95% CI: 1.5% to 3.8%), G6PC2 (rs560887) 2.5% (1.9%
to 3.2%), ADCY5 (rs11708067) 1.5% (0.7% to 2.2%),
DGKB (rs2191349) 0.8% (0.3% to 1.3%), and ADRA2A
(rs10885122) 0.5% (1.1% to 2.0%) (Fig. 3). Combining
genotypes by number of glucose-increasing alleles, an
increasing number of glucose-increasing alleles associatedwith an up to 4.8% (3.6% to 6.0%) increase in nonfasting
glucose levels.
Genotype and IHD and MI. Assuming that increased
nonfasting glucose levels have a causal effect on risk of IHD
and MI, lifelong increased glucose levels due to genetic
variants should confer a similar increase in risk of IHD and
MI as that observed for increased glucose levels encountered
in the general population. For example, the 4.8% increase in
nonfasting glucose levels seen for 8 glucose-increasing alleles
(Fig. 3) would theoretically predict an increased risk of IHD
and MI with hazard ratios of 1.04 (95% CI: 1.03 to 1.05) and
1.04 (95% CI: 1.03 to 1.05) (Online Fig. 3). In accordance
with this, the observed odds ratio for IHD increased as a
function of the glucose-increasing alleles with the largest
glucose-increasing effects (p trend 0.01) (Online Fig. 3); the
Figure 1 Cumulative Incidence Using Kaplan-Meier
Estimates of IHD and MI
Cumulative incidence using Kaplan-Meier estimates of (A) ischemic heart dis-
ease (IHD) and (B) myocardial infarction (MI) in percent as a function of age at
event. Subjects with IHD or MI before study enrollment were excluded, result-
ing in 16,318 subjects followed up for as long as 35 years with respect to inci-
dent events. Solid line indicates 5 mmol/l; long-dashed line indicates 5 to
6.9 mmol/l; shorter-dashed line indicates 7 to 8.9 mmol/l; shortest-dashed
line indicates 9 to 10.9 mmol/l; and dotted line indicates 11 mmol/l.
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Nonfasting plasma glucose levels were measured in 16,568 subjects who participated in the 1976 to 1978, 1981 to 1983, 1991 to 1994, and/or 2001 to 2003
examinations of the Copenhagen City Heart Study. Results are shown for (A) ischemic heart disease (IHD) and (B) myocardial infarction (MI). Participants with IHD or MI
before study enrollment were excluded, resulting in 16,318 subjects followed up for as long as 35 years with respect to incident events. Basic multifactorial adjustment
was for age, sex, current smoking, menopause, and statin use. The fully multifactorially adjusted model additionally included body mass index, total cholesterol, high-
density lipoprotein (HDL) cholesterol, and hypertension. CI  confidence interval; HR  hazard ratio.
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uted among the genotypes, confirming that these genotypes are
largely unconfounded by such factors (Online Table 2). Results
Figure 2 Continuedfor MI were similar (Online Fig. 3).Nonfasting glucose and IHD and MI causal estimates.
A potential causal effect of increased nonfasting glucose
levels on increased risk of IHD and MI was also examined
using instrumental variable analysis. A 1-mmol/l (18-mg/
2362 Benn et al. JACC Vol. 59, No. 25, 2012
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associated with a causal odds ratio for IHD of 1.25 (95% CI:
1.03 to 1.52) and MI of 1.69 (95% CI: 1.28 to 2.23), and
the observed multifactorially adjusted hazard ratio for a
similar increase was 1.18 (95% CI: 1.15 to 1.22) for IHD
and 1.09 (95% CI: 1.07 to 1.11) for MI (Fig. 4). The
corresponding causal odds ratios for IHD and MI were 1.36
(95% CI: 1.05 to 1.77) and 1.54 (95% CI: 1.05 to 2.27),
respectively, using effect estimates for per allele increases in
fasting glucose levels from the literature.
Discussion
The main finding of this study is that both observational
and genetically elevated nonfasting glucose levels are asso-
ciated with increased risk of IHD and MI. This finding is
compatible with elevated glucose levels per se being causally
related to the development of IHD and MI.
Overall, evidence for or against a causal contribution of
glucose to the pathogenesis of macrovascular disease, in-
Gene Genotype No. ofparticipants Mean (standard error) P-trend
GCK rs4607517,G>A
100.0<511,84GG
560,81AG
517,1AA
G6PC2 rs560887,C>T
100.0<193,6TT
586,82TC
147,23CC
ADCY5 rs11708067,A>G
100.0<880,4GG
715,52GA
292,83AA
DGKB rs2191349,T>G
100.0<730,61GG
539,33GT
029,71TT
ADRA2A rs10885122,G>T
20.0988TT
325,31TG
394,35GG
Glucose increasing alleles
100.0<310,23-0
364,64
726,415
099,916
980,617
640,78
Nonfasting glucose, mmol/L
   
Figure 3 Nonfasting Plasma Glucose Levels as a Function of G
Glucose-increasing alleles were combinations of genotypes with glucose-increasing
binations were excluded because of reduced statistical power. This was examined
General Population Study combined, irrespective of other cardiovascular risk facto
levels reported from genome-wide association studies (GWAS) using plasma gluco
to mg/dl, multiply by 18.cluding IHD and MI, can come from 5 types of evidence;that is, conventional epidemiology, mechanistic studies,
animal models, randomized intervention trials, and Men-
delian randomization studies like the present (22,23).
1) Previous prospective epidemiologic studies showed that
elevated fasting glucose levels associate with increased IHD
and MI risk even at nondiabetic glucose levels (1,2). Our
results using nonfasting glucose levels are in agreement with
this, and confirm that even after adjustment for obesity,
dyslipidemia, and hypertension, elevated IHD and MI risk
remain. 2) Results from in vitro and animal studies have
suggested several mechanisms by which glucose may con-
tribute to macrovascular disease: increased glucose levels,
free fatty acids, and insulin resistance together leads to
oxidative stress, activation of protein kinase C isoforms,
formation of advanced glycation end product, and nonen-
zymatic glycation of low-density lipoprotein, apolipopro-
teins, and clotting factors, collectively resulting in vasocon-
striction, inflammation, and thrombosis (2,24,25). 3) In
animal models with experimental hypercholesterolemia or
nge in glucose levels, %
% confidence interval)
Per allele effect,
mmol/L (SEM)
Per allele effect,
mmol/L (SEM);
GWAS (5,6,8)
Risk allele
frequency;
GWAS
)700.0(260.0)610.0(370.00
)4.1-6.0(0.1
81.0)8.3-5.1(7.2
)400.0(460.0)900.0(860.00
)5.1-2.0(9.0
82.0)2.3-9.1(5.2
)300.0(720.0)110.0(930.00
)9.0-6.0-(1.0
87.0)2.2-7.0(5.1
)7800.0(640.0)700.0(220.00
)0.1-1.0(5.0
25.0)3.1-3.0(8.0
)400.0(220.0)220.0(710.00
)7.1-5.1-(1.0
78.0)0.2-1.1-(5.0
0
)1.2-3.0-(9.0
)7.2-5.0(6.1
)1.4-8.1(9.2
)6.4-3.2(4.3
)0.6-6.3(8.4
pe in General Population
ts; the most common genotype combinations are shown, whereas the rarer com-
,914 participants from the Copenhagen City Heart Study and the Copenhagen
reatment for diabetes mellitus. Estimates of effect on fasting plasma glucose
el as the phenotype are reported in the right column. To convert mmol/l glucoseCha
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meta-analysis of randomized intervention trials (27–32)
showed that intensive glycemic control in patients with
diabetes mellitus was associated with a 15% reduction in risk
of IHD (3). However, in all included studies, intensive
glycemic control also had beneficial effects on obesity,
dyslipidemia, and/or hypertension, obscuring the isolated
effect of reduced glucose levels, and this issue remains
unresolved. 5) Using a Mendelian randomization approach
free from reverse causation and unconfounded by obesity,
dyslipidemia, and hypertension, we here found that both
observational and genetic lifelong elevated nonfasting or
fasting glucose levels associate with increased risk of IHD
and MI. In the present study, we use genotypes associated
with glucose levels in the nondiabetic range and not asso-
ciated with diabetes mellitus in our general population
Figure 4 Summary of Causal Effects of Increased Nonfasting G
Studies’ summary of the causal effect of increased nonfasting glucose on increas
in the Copenhagen City Heart Study, the Copenhagen General Population Study, a
not genotyped for lack of deoxyribonucleic acid; and for participants genotyped, nu
ing glucose levels on risk of IHD and MI was estimated by the association betwee
and MI, using instrumental variable analysis by 2-stage least-squares regression a
pared to the observational prospective increased risk of IHD and MI, respectively,
population, the Copenhagen City Heart Study, given as a multifactorially adjusted
genetic increase in nonfasting glucose levels are also given for individual and com
of genotype to variation in plasma glucose levels in percent) are from the first-stag
tion between genotype and risk, imputed glucose values were included in part of t
1-mmol/l (18-mg/dl) genetic increase in nonfasting glucose levels on risk of IHD a
genome-wide association studies specifically aimed at identifying genes associate
The p value comparison is between the estimate from observational epidemiology
cose to mg/dl, multiply by 18.samples, suggesting that the increased risk of IHD is more olikely due to glucose per se, rather than mediated through
diabetes mellitus. A recent Mendelian randomization study
support that elevated fasting plasma glucose levels may also
be causally related to increased intima-media thickness (33).
herefore, these 5 different types of evidence collectively
uggest that elevated plasma glucose per se might be causally
elated to the development of IHD and MI.
From a clinical standpoint, our confirmation of increased
onfasting glucose as a marker of increased IHD risk
uggests that nonfasting values may be used in risk stratifi-
ation, whereas for diagnostic purposes, fasting values are
equired. Although nonfasting/post-prandial glucose levels
re more variable than fasting levels, risk of cardiovascular
isease is more strongly associated with nonfasting/post-
randial hyperglycemia than fasting hyperglycemia (34).
he exact reason for this is not known, but it has been
e on Increased Risk of IHD and MI
of ischemic heart disease (IHD) and myocardial infarction (MI). This was tested
Copenhagen Ischemic Heart Disease Study combined; 6,448 participants were
vary slightly from genotype to genotype. The causal effect of increased nonfast-
mmol/l (18-mg/dl) genetic increase in nonfasting glucose levels and risk of IHD
en as an odds ratio (OR) with a 95% confidence interval (CI). This risk is com-
iated with a 1-mmol/l (18-mg/dl) increase in nonfasting glucose in the general
gression hazard ratio (HR) with a 95% CI. Odds ratios for a 1-mmol/l (18-mg/dl)
genotypes. F-statistics (evaluation of strength of instrument) and R2 (contribution
ession analysis. In the second-stage regression analysis studying the associa-
es in the Copenhagen Ischemic Heart Disease Study. The causal effect of a
was also estimated using effect sizes for genotypes previously reported from
plasma glucose levels. The p value is for significance of hazard ratio/odds ratio.
e causal estimate from instrumental variable analysis. To convert mmol/l glu-lucos
ed risk
nd the
mbers
n a 1-
nd giv
assoc
Cox re
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e regr
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nd MI
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disease, have elevated nonfasting/post-prandial glucose lev-
els, but usually fasting blood glucose levels within the
normal range (35). The use of nonfasting glucose measure-
ments may explain the relatively high observational risk
estimates in the present study compared to others (1), but
this difference may also in part be because we were able to
adjust for regression dilution bias (18).
Strengths of the present study are that we had sufficient
statistical power to document increased risk of IHD and MI
as a function of glucose-increasing genotypes. Another
strength of the present study was that all participants were
white persons of Danish descent, thus effectively excluding
admixture as a potential problem in our study.
A potential limitation of the present Mendelian random-
ization approach is that, apart from their involvement in
glucose regulation and metabolism, the presently studied
genetic variants may have pleiotropic effects on other
cardiovascular risk factors or directly on IHD and MI risk
unrelated to nonfasting glucose levels. However, we did not
find any consistent associations with age, BMI, levels of
total cholesterol or HDL cholesterol, or frequency of
metabolic syndrome, diabetes mellitus, use of insulin or oral
antidiabetic medication, hypertension, current smoking,
menopause, or statin use across genotypes. Nevertheless, the
ADCY5 and DGKB genes are reported to be involved in
ymphacetic and parasymphacetic regulation of heart rate
10) and may have an effect on IHD and MI risk through 1
f these pathways. Furthermore, ADRA2A is directly in-
olved in lipolysis and is associated with risk of attention
eficit/hyperactive disorder (11). Except for increased birth
eight reported to be associated with GCK genotype, no
leiotropic effects have been reported for the GCK and
6PC2 genes with the largest effects on nonfasting glucose
evels in the present study. Using 1 genotype reduces the
ffect of unknown pleiotropy of the genotypes and reduces the
nfluence of a genotype directly associated with risk of IHD
nd MI unrelated to nonfasting glucose levels, but may result
n an overestimation of the causal risk (4). Another potential
imitation of the present study is the modest contribution of
enotypes to the variation in nonfasting glucose levels (weak
nstrument bias and unreliable instruments bias) and the use of
genotypes as instruments. To evaluate this, we first used F
tatistics to test the strength of the instruments and found that
of 5 instruments were excellent, and combined, all 5
enotypes were good instruments (F 10). We then repeated
he instrumental variable analyses using effect estimates from
ublished genome-wide association studies. The causal esti-
ate using external independent effect sizes corresponded with
he causal estimate from the present study populations, sug-
esting that such a bias is unlikely. Also, we studied white
ubjects only, and therefore our results may not necessarily
ranslate to other races. A known limitation of prospective
tudies using a baseline nonfasting measurement for classifica-
ion is misclassification due to regression dilution bias, which is
he fact that extreme values at baseline tend to attenuate overime and regress toward the mean value of measurements (4).
n the present study, we corrected for this using results from
ubjects with 1 measurement over time to estimate the
egree of regression dilution.
onclusions
oth elevated observational and genetic nonfasting glucose
evels are associated with increased risk of IHD and MI.
hese data are compatible with a causal association.
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